Nasdaq
$1.04▲ 2.46%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.6MShares out 3.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
18- 10.13Pre-market26.10.13 21:466-KKey event#●●●#●●●
IceCure Medical Ltd.Bullish
IceCure Medical highlighted clinical data and strong physician engagement for its ProSense breast cancer cryoablation system at the EUSOBI 2026 annual meeting. The company reported 12-month clinical results showing an objective response rate of 97.5% for patients treated with cryoablation plus endocrine therapy and 91.7% for those treated with cryoablation alone.…more
$1.04+2.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:156-KKey event
IceCure Medical Ltd.
IceCure Medical has amended the agenda for its Annual and Special General Meeting of Shareholders scheduled for November 2, 2026. Key proposals include the reappointment of the independent auditor and the approval of equity-based compensation grants of 404,901 RSUs to CEO Eyal Shamir and 230,577 RSUs to Chairman Ron Mayron.…more
$1.04+2.46%vs prev closeView filingShare - 10.5Pre-market26.10.05 19:306-KKey event
IceCure Medical Ltd.
IceCure Medical's application for a permanent CPT category I code for its cryoablation treatment of breast tumors was rejected by the American Medical Association. The existing CPT category III code remains in place, allowing for continued CMS reimbursement of approximately $4,000 per facility fee without affecting current commercial operations. The company plans to expand clinical evidence and potentially resubmit the application in June 2027.…more
$1.04+2.46%vs prev closeView filingShare
17 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 20:56#●●●#●●●
IceCure Medical Enrolls First Patients in U.S. ProSense Breast Cancer Study…more
IceCure Medical has enrolled the first two patients in its 400-patient U.S. post-marketing study for the ProSense breast cancer cryoablation system. While this study marks a step toward broader adoption, it remains in the early stages and does not yet provide immediate financial impact.…more
$1.04+2.46%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.13Pre-market26.10.13 21:10
●●●●●●●● ●●●●● ●●●●●●
IceCure Medical presented 12-month clinical data and physician workshops on its ProSense cryoablation system at the European Society of Breast Imaging annual meeting. The study demonstrated high objective response rates for breast cancer patients treated with cryoablation, both alone and in combination with endocrine therapy.…more
$1.04+2.46%vs prev closeShareBenzinga - 10.6Pre-market26.10.06 21:29
●●●●●●●● ●●●●● ●●●●●●
IceCure Medical has added Legacy Health as a new U.S. clinical site for its FDA-approved post-marketing ChoICE study evaluating the ProSense cryoablation system. This expansion aims to increase patient enrollment and gather further real-world clinical data on the treatment of low-risk breast cancer.…more
$1.04+2.46%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report